Pharmaceutical intermediates
Maxacalcitol Intermediates
5 pharmaceutical intermediates for Maxacalcitol. Indication: Secondary hyperparathyroidism; Hyperparathyroidism.
About Maxacalcitol
- Originator
- Chugai Pharmaceutical Co., Ltd
- Indication
- Secondary hyperparathyroidism; Hyperparathyroidism
- Approved Date
- 01/21/2011
Available intermediates
5 intermediates currently listed for Maxacalcitol. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| PHOSPHINE OXIDE, [2-[3,5-BIS [[(1,1-DIMETHYLETHYL) DIMETHYLSILY]OXY]-2-METHYLENECYCLOHEXYLIDENE]ETHYL]DIPHENYL-,[3S-(1Z,3A,5B0)] | 81522-68-1 | / | / |
| (1S,3aR,4S,7aS)-1-((S)-1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyloctahydro-1H-inden-4-ol | 192573-37-8 | / | / |
| (1S,3aR,7aR)-1-((S)-1-(3-hydroxy-3-Methylbutoxy)ethyl)-7a-Methylhexahydro-1H-inden-4(2H)-one | 884488-07-7 | / | / |
| (1S,3aR,7aR)-Octahydro-7a-Methyl-1-((1S)-1-(3-Methyl-3-((triMethylsilyl)oxy)butoxy)ethyl)-4H-Inden-4-one | 192573-33-4 | / | / |
| (Z)-2-((3S,5R)-3,5-bis((tert-butyldiMethylsilyl)oxy)-2-Methylenecyclohexylidene)ethanol | 81506-24-3 | / | / |
Building toward Maxacalcitol?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →